PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
about
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Targeting neurotransmitter receptors with nanoparticles in vivo allows single-molecule tracking in acute brain slicesInvolvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesiaAstrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat modelsRegulation of dopamine D1 receptor dynamics within the postsynaptic density of hippocampal glutamate synapsesMotor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95In adult female hamsters hypothyroidism stimulates D1 receptor-mediated breathing without altering D1 receptor expression.Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's ratsAberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapsesNeuroleptic intolerance in patients with anti-NMDAR encephalitis.Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors.L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice.Proteomic Analysis of Cerebellum in Common Marmoset Exposed to Methylmercury.Postsynaptic Density Protein 95 in the Striosome and Matrix Compartments of the Human Neostriatum.GSK-3β Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia.Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.[PSD-95 expression controls L-Dopa dyskinesia].Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.The formation of zirconium hexacyanoferrate(ii) nanoparticles and their application in the highly sensitive determination of dopamine based on enhanced resonance Rayleigh scatteringL-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
P2860
Q27324174-5350AE09-F5F2-4EED-B1E3-3E6D8E25BFAFQ27324563-37F57BD2-C491-48F0-8093-84B2A5339E67Q33725654-B1B14002-5028-4832-9335-F8AF6914E420Q34238909-95D98757-CDA0-4B11-8EEF-E9071775074BQ34783370-FE00140E-2F3E-4ABA-A78B-D157FDDE3EF2Q34990075-11BD6E19-1E50-49D2-8500-FBA5057C9F37Q35526468-04618C03-0131-4D59-A34B-219390608EADQ36326548-2C15A24F-2280-4BFE-8A70-6F3241386E69Q36557687-F01BC213-6907-4923-A176-1C913899E7D7Q37048087-56F6E746-551D-492A-8394-27BCEEF1AD84Q37216597-8311C8E7-2556-4C6C-ADB0-304B733F993AQ37276714-F62246C4-BE41-4E4F-B325-EBED1FA4252CQ37344222-CDFD40B9-475F-4F74-B0D2-226266EAF317Q37486030-04686D8F-BC85-49F4-A34C-786197674F9AQ38133757-4B71AC8F-5BE2-4C6E-8C90-EE6B1BDE9D3DQ38207680-64705237-E45C-4110-B5B1-C892A9CFAD95Q38267957-D0AF0765-E22E-4369-8E5A-998AD332617DQ38942654-A962B113-556F-48FF-A32E-27156C58D373Q38951947-9C21CBB3-67E7-4209-9492-36007BDB4E2BQ39012371-85F4D35E-7604-4FFC-A200-08678BCFE090Q39172080-2C0E3987-17EE-4BFA-B0EF-3C162945240DQ39981493-C47E413B-9FB1-4312-80ED-B7324E83804CQ40181237-171A32F1-4C90-4031-A0C4-A92CCAE92AB5Q42645980-F2136992-1E13-4F81-AA2A-C80F0B74289BQ42702178-E6994E69-07CA-4B58-B28E-E9EE8A4016B8Q43150781-B3915406-67EA-4254-AF27-605CCA83E438Q48389256-CB13005E-8383-4719-B59C-F9604F4584D1Q48867898-EE4A5AB5-5DB0-4C44-9A62-3C65766AA181Q48956010-6E9BCD92-9D8B-4250-8295-660D47332FA4Q49357267-F6507B46-2E84-48CF-96FD-54DA0BA25B20Q51832640-753EBDC2-0066-420B-B9D4-8098BE5D0C78Q53642390-6C7815C6-2EC6-4FFA-9523-C6EB1749DF86Q54446796-CD41A575-309F-4FA4-B856-AC8644D407EBQ55335504-8984F960-76D4-43D2-A793-38785901FAB6Q57376631-B1E73D25-86DC-47F2-B381-5AB5EDE08FA7Q59136653-B2096E11-2998-424E-9DBB-32D2E50B86ED
P2860
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@ast
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@en
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@nl
type
label
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@ast
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@en
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@nl
prefLabel
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@ast
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@en
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@nl
P2093
P2860
P50
P3181
P356
P1476
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
@en
P2093
Amandine Berthet
Audrey Martinez
Benjamin Dehay
Bertrand Bloch
Elisabeth Normand
Gregory Porras
Laurent Groc
Marie-Laure Martin-Négrier
P2860
P304
P3181
P356
10.1172/JCI59426
P407
P577
2012-10-08T00:00:00Z